Hoffmann-La Roche Limited

In 1999, two science-based companies with shared visions came together to form AstraZeneca: Sweden's Astra AB and the UK's Zeneca Group PLC. This strategic merger combined decades of pharmaceutical expertise, creating a global powerhouse uniquely positioned to push the boundaries of scientific discovery. What began as a union of strengths has evolved into a relentless pursuit of breakthrough therapies, with the company investing billions annually in research and development to transform patient outcomes across oncology, biopharmaceuticals, respiratory, and rare diseases. Today, AstraZeneca stands at the forefront of precision medicine and next-generation therapeutics, harnessing the power of data science, AI, and innovative technologies like cell therapies. With 197 projects in the pipeline and 16 blockbuster medicines, the company operates from six strategic R&D centres spanning Cambridge, Gothenburg, Gaithersburg, Boston, Shanghai, and Beijing. Their bold aspiration to deliver 20 new medicines by 2030 reflects an unwavering commitment to following the science and putting patients first - values that have driven every decision since that pivotal merger more than two decades ago.

At Agenus, we're driven by a singular, unwavering mission: to end the suffering of cancer patients. For over 30 years, our team of scientists, researchers, and professionals has been united by this purpose, working collaboratively across the US and Europe to discover, develop, and manufacture breakthrough immuno-oncology therapies. Our research and innovation engine has built a comprehensive pipeline of novel immunotherapies that empower the body to recognize and eliminate disease. We believe that the key to transforming cancer treatment lies in harnessing the full power of the immune system - activating it to do what it was meant to do. Our culture is defined by scientific excellence, relentless innovation, and an unwavering focus on patients. We thrive on tackling the toughest challenges in oncology, particularly in areas where current therapies fall short - cold tumors and late-stage cancers that have resisted traditional treatments. The people who thrive here are those who share our passion for making a meaningful difference, who embrace collaboration across disciplines, and who are motivated by the potential to deliver curative therapies to patients who need them most. Every day, we're pushing the boundaries of what's possible in immunotherapy, united by our vision of a future where more patients live longer, fuller lives.

Monte Rosa Therapeutics is a clinical-stage biotechnology company focused on developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases. The company’s work centers on degrading proteins - 'Degrading Proteins, Making Medicines' - and advancing precision approaches that target undruggable or inadequately drugged proteins with unprecedented specificity. On its website, the team is described as combining expertise in molecular glue degrader (MGD) chemistry, artificial intelligence (AI), structural biology, and proteomics. Monte Rosa’s QuEEN
9 (Quantitative and Engineered Elimination of Neosubstrates) discovery engine is described as using AI-guided chemistry alongside diverse chemical libraries, structural biology, and proteomics to identify degradable protein targets and rationally design MGDs. The company positions this platform as enabling access to a wide-ranging, differentiated target space across multiple therapeutic areas, and references advancing multiple MGD programs through its pipeline. The company is headquartered in Boston, Massachusetts, and also lists a Basel, Switzerland location on its site.

Founded in 1920, Endo International plc is a specialty pharmaceutical company with global headquarters in Dublin, Ireland, and U.S. headquarters in Malvern, Pennsylvania. The company has historically focused on developing, manufacturing, and marketing quality branded and generic pharmaceutical products across key therapeutic areas including pain management, urology, and oncology. Endo's product portfolio includes widely recognized medications such as Percocet, along with numerous generic and branded specialty pharmaceuticals. The company operates through multiple business segments and has grown through strategic acquisitions, including the purchase of American Medical Systems in 2011 and Par Pharmaceutical in 2015. In a significant corporate development, Endo merged with Mallinckrodt Pharmaceuticals on July 31, 2025, creating a combined entity that subsequently divided into two independent companies: Par Health, focusing on generics and sterile injectables, and Keenova Therapeutics, concentrating on specialty therapeutics.

At Novonesis, we believe that solutions rooted in biology are the key to tackling the biggest challenges our world faces. Our team of more than 10,000 colleagues across 30+ industries works together to transform how the world produces, consumes, and lives. We operate with a culture of collaboration and innovation, drawing on over a century of combined expertise from our heritage companies. Our people thrive in an environment where sustainability is not just a goal but a fundamental part of how we work - where every contribution helps build healthier lives and a healthier planet. We are inherently sustainable because we draw from nature, and we embrace the diverse perspectives that drive our innovation forward. Our inclusive culture fosters belonging and respect, ensuring that everyone can bring their authentic selves to work while making meaningful impact. Whether developing enzymes, functional proteins, or microorganisms, we operate with the conviction that biology holds the answers to humanity's most pressing challenges. We empower our teams with real ownership and cross-functional collaboration, optimizing for impact rather than hierarchy.

The purpose of Idorsia is to discover, develop, and commercialize innovative medicines to help more patients. We have more ideas, we see more opportunities, and we want to transform the horizon of therapeutic options. Headquartered in Switzerland – a biotech-hub of Europe – Idorsia is a high-potential biopharmaceutical company, specialized in the discovery, development and commercialization of innovative small molecules. Our team is dedicated to bringing innovative medicines from bench to bedside, with operations spanning multiple locations across North America, Europe, and Asia. We conduct research, clinical development, and commercial operations out of these global locations. Idorsia's corporate responsibility efforts encompass employee development and diversity, governance and ethics, as well as the organization's economic, environmental, and social performance.